ALISO VIEJO, CA — (Marketwire) — 08/29/11 — (OTCBB: CNSO) today announced that in a recent retrospective study, physicians using PEER Outcome data reported reduced trial-and-error medication selection for eating disorders patients with comorbid major depression or bipolar disorder. The physicians, who reviewed two-year pre-treatment data and between two- to five-year follow-up data, found that study patients experienced significantly decreased depressive symptoms and overall 53 percent fewer hospitalization days, which significantly reduced overall healthcare costs.
In addition, according to the study, the wide variety of medications successfully used to treat study patients suggests there is no single class of medications for treating eating disorders. Instead, by developing individual treatment regimes correlated to a patient-s unique neurophysiology, physicians were able to achieve significant reductions in trial-and-error practice. The subjects had previously failed an average of 5.7 medications over an average of nine years.
The findings are reported in a paper entitled, “Retrospective Chart Review of a Referenced EEG Database in Assisting Medication Selection for Treatment of Depression in Patients with Eating Disorders.” The paper has been accepted for publication by Neuropsychiatric Disease and Treatment, the journal of the International Neuropsychiatric Association (INA).
“Eating disorders are associated with a high mortality rate,” said James M. Greenblatt, M.D., lead author of the study. “Currently, there is only one medication, fluoxetine, approved by the U.S. Food and Drug Administration for the treatment of bulimia nervosa, and no drug approved by the FDA for the treatment of anorexia nervosa or Eating Disorder Not Otherwise Specified. Without evidence-based research to support pharmacotherapy for eating disorders, physician choices are little more than educated guesses. These study results suggest that physicians who develop patient-specific treatment regimes using PEER Outcomes and other data reduce their use of costly trial and error prescribing. These physicians reduce patient suffering, improve outcomes, reduce hospitalization and can significantly curb health care costs.”
The study group focused on 22 eating disorders patients with a median age of 21 years. The average age of onset of eating disorders symptoms was 15.6 years.
The primary comorbid diagnosis for each patient included either major depressive disorder (MDD) (18/22: 82 percent) or bipolar disorder (BPD) (4/22: 18 percent). Additionally, 12 individuals were diagnosed with comorbid obsessive-compulsive disorder (OCD), three with attention deficit disorder (ADHD), five with past alcohol abuse/dependence, six with generalized anxiety disorder (GAD), and one with post-traumatic stress disorder (PTSD).
The PEER Outcome data used by the physicians was provided by CNS Response. CNS Response-s enables physicians to compare and learn which medication treatments have been effective, and which have been ineffective when used by their peers in treating patients with similar EEGs. The collection of shared physician experience builds on the company-s original physician-developed database, Referenced-EEG® (rEEG®).
According to the study:
Not only did many of the patients- depression and severity scores normalize quickly and significantly, but they also continued to improve during the two- to five-year follow-up period.
As early as six months from starting treatment, 11 patients (50 percent) reported complete remission of depression symptoms, nine reported mild depression symptoms, and two remained moderately depressed.
In total, prior to physician use of PEER Outcome data, 18 patients (82 percent) had inpatient hospitalizations; only seven (32 percent) required hospitalizations in the two- to five-year follow-up period.
The full paper is expected to appear within weeks through the journal-s online site at . Once published, the paper may be downloaded at no cost.
CNS Response provides reference data and analytic tools for clinicians and researchers in psychiatry. While treatment for mental disorders has doubled in the last 20 years, it is estimated that 17 million Americans have failed two or more medication therapies for their mental disorder. The company recently launched the Psychiatric EEG Evaluation Registry, or PEER Online, a new registry and reporting platform that allows medical professionals to exchange treatment outcome data for patients referenced to objective neurophysiology data obtained through an EEG. PEER Online builds on the company-s original physician-developed database, Referenced-EEG® (rEEG®). Avoiding trial and error pharmacotherapy, the dominant approach for psychiatric treatment, is the objective of PEER Online.
To read more about the benefits of this patented technology for patients, physicians and payers, please visit . Medical professionals interested in learning more can contact CNS Response at .
Except for the historical information contained herein, the matters discussed are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements involve risks and uncertainties as set forth in the Company-s filings with the Securities and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from any forward-looking statements made herein.
Marty Tullio
Managing Partner
McCloud Communications, LLC
949.553.9748
Joyce Johannson
Johannson Communications
612.927.4543 (office)
612.845.3080 (cell)
You must be logged in to post a comment Login